# Kaoru Kubota

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kaoru-kubota/

## Facts

| Field | Value |
| --- | --- |
| Citations | 32,750 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 60 |
| i10-index | 184 |
| Last Known Institution | Nippon Medical School |
| OpenAlex ID | https://openalex.org/A5100669294 |
| ORCID iD | https://orcid.org/0000-0003-0367-2606 |
| Works | 434 |

## Researcher papers

- [The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer](https://scholariq.org/papers/the-iaslc-lung-cancer-staging-project-proposals-for-revision-of-the-tnm-stage/)
- [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/)
- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer](https://scholariq.org/papers/the-iaslc-lung-cancer-staging-project-proposals-for-coding-t-categories-for/)
- [Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan](https://scholariq.org/papers/randomized-phase-iii-study-of-cisplatin-plus-irinotecan-versus-carboplatin-plus/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer](https://scholariq.org/papers/the-iaslc-lung-cancer-staging-project-external-validation-of-the-revision-of-the/)
- [The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer](https://scholariq.org/papers/the-international-association-for-the-study-of-lung-cancer-lung-cancer-staging/)
- [Predominant infiltration of macrophages and CD8<sup>+</sup> T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer](https://scholariq.org/papers/predominant-infiltration-of-macrophages-and-cd8-sup-sup-t-cells-in-cancer-nests/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Nippon Medical School](https://scholariq.org/institutions/nippon-medical-school/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.